Ttbio Corp.
Ttbio Corp. manufactures, sells, and maintains medical devices under the TTBIO brand name in Taiwan and the United States. The company offers high and low-speed hand piece products, dental spare parts, service rotors, maintenance units, electric hand piece systems, and precision-machined components. It serves various industries, including medical, automotive, aerospace, security, computer compone… Read more
Ttbio Corp. (6493) - Net Assets
Latest net assets as of June 2025: NT$286.46 Million TWD
Based on the latest financial reports, Ttbio Corp. (6493) has net assets worth NT$286.46 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$640.77 Million) and total liabilities (NT$354.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$286.46 Million |
| % of Total Assets | 44.71% |
| Annual Growth Rate | -1.72% |
| 5-Year Change | 3.45% |
| 10-Year Change | N/A |
| Growth Volatility | 7.41 |
Ttbio Corp. - Net Assets Trend (2019–2024)
This chart illustrates how Ttbio Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ttbio Corp. (2019–2024)
The table below shows the annual net assets of Ttbio Corp. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$295.11 Million | -1.53% |
| 2023-12-31 | NT$299.69 Million | -7.25% |
| 2022-12-31 | NT$323.11 Million | +9.35% |
| 2021-12-31 | NT$295.47 Million | +3.58% |
| 2020-12-31 | NT$285.26 Million | -11.37% |
| 2019-12-31 | NT$321.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ttbio Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 83.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$8.45 Million | 2.86% |
| Common Stock | NT$240.50 Million | 81.49% |
| Other Components | NT$46.17 Million | 15.64% |
| Total Equity | NT$295.11 Million | 100.00% |
Ttbio Corp. Competitors by Market Cap
The table below lists competitors of Ttbio Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Energoaparatura S.A.
WAR:ENP
|
$3.34 Million |
|
Hour Loop Inc
NASDAQ:HOUR
|
$3.34 Million |
|
Huntington Exploration Inc
PINK:HEXPF
|
$3.35 Million |
|
Freedom Internet Group Inc
PINK:FIGI
|
$3.35 Million |
|
HB Global Ltd
KLSE:5187
|
$3.34 Million |
|
RFG Holdings Ltd
JSE:RFG
|
$3.34 Million |
|
Universal Ibogaine Inc
PINK:IBOGF
|
$3.34 Million |
|
Bioalpha Holdings Bhd
KLSE:0179
|
$3.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ttbio Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 299,689,000 to 295,111,000, a change of -4,578,000 (-1.5%).
- Net income of 2,590,000 contributed positively to equity growth.
- Dividend payments of 7,215,000 reduced retained earnings.
- Other comprehensive income increased equity by 14,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$2.59 Million | +0.88% |
| Dividends Paid | NT$7.21 Million | -2.44% |
| Other Comprehensive Income | NT$15.00K | +0.01% |
| Other Changes | NT$32.00K | +0.01% |
| Total Change | NT$- | -1.53% |
Book Value vs Market Value Analysis
This analysis compares Ttbio Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.94x to 2.12x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$13.37 | NT$25.95 | x |
| 2020-12-31 | NT$11.84 | NT$25.95 | x |
| 2021-12-31 | NT$12.27 | NT$25.95 | x |
| 2022-12-31 | NT$13.41 | NT$25.95 | x |
| 2023-12-31 | NT$12.45 | NT$25.95 | x |
| 2024-12-31 | NT$12.27 | NT$25.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ttbio Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.83%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 2.06x
- Recent ROE (0.88%) is below the historical average (7.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 11.80% | 14.22% | 0.57x | 1.46x | NT$5.80 Million |
| 2020 | 16.08% | 25.64% | 0.44x | 1.44x | NT$17.35 Million |
| 2021 | 3.90% | 3.77% | 0.66x | 1.57x | NT$-18.01 Million |
| 2022 | 12.32% | 9.50% | 0.80x | 1.63x | NT$7.48 Million |
| 2023 | 2.23% | 2.10% | 0.62x | 1.71x | NT$-23.29 Million |
| 2024 | 0.88% | 0.83% | 0.51x | 2.06x | NT$-26.92 Million |
Industry Comparison
This section compares Ttbio Corp.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,796,147,300
- Average return on equity (ROE) among peers: 10.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ttbio Corp. (6493) | NT$286.46 Million | 11.80% | 1.24x | $3.34 Million |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.11K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |